GlaxoSmithKline PLC ADR
NYSE: GSK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Updated 2026-10-28
GlaxoSmithKline PLC ADR (GSK) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.55B | $31.00B | $39.39B | $42.86B | $42.05B | $41.08B | $41.48B | $42.09B | $40.65B | $53.45B | $59.08B | $56.38B | $58.07B | $105.57B | $109.95B | $107.14B | $60.15B | $75.22B | $59.46B | $61.12B |
| Cash & equivalents | $2.00B | $3.38B | $5.62B | $6.54B | $6.06B | $5.71B | $4.18B | $5.53B | $4.34B | $5.83B | $4.90B | $3.83B | $3.87B | $6.24B | $8.60B | $5.79B | $3.72B | $3.74B | $3.69B | $3.40B |
| Current assets | $10.99B | $13.63B | $17.27B | $17.57B | $16.04B | $16.17B | $13.69B | $15.23B | $14.68B | $16.59B | $16.71B | $15.91B | $16.93B | $25.82B | $27.68B | $25.29B | $20.77B | $23.77B | $17.00B | $17.51B |
| Total liabilities | $15.90B | $21.09B | $31.07B | $32.12B | $32.31B | $32.25B | $34.73B | $34.27B | $35.72B | $44.57B | $54.12B | $52.89B | $54.39B | $81.25B | $81.50B | $78.23B | $50.05B | $58.91B | $46.38B | $45.16B |
| Current liabilities | $7.26B | $10.35B | $10.02B | $12.12B | $12.62B | $15.01B | $13.81B | $13.68B | $13.29B | $13.42B | $19.00B | $26.57B | $22.49B | $31.86B | $30.28B | $32.06B | $22.81B | $26.86B | $21.70B | $21.39B |
| Long-term debt | $9.35B | $14.02B | $22.27B | $23.90B | $22.79B | $18.96B | $23.86B | $25.62B | $24.68B | $15.28B | $14.62B | $14.22B | $20.23B | $22.58B | $23.43B | $20.57B | $17.04B | $14.15B | $13.70B | $14.02B |
| Shareholder equity | $9.39B | $9.60B | $7.93B | $10.01B | $8.89B | $8.03B | $5.81B | $7.00B | $4.94B | $8.88B | $4.96B | $3.49B | $3.78B | $15.11B | $19.94B | $20.39B | $10.60B | $17.01B | $13.67B | $16.38B |
| Retained earnings | $6.96B | $6.47B | $4.62B | $6.32B | $4.78B | $3.37B | $652.00M | $913.00M | $-2.07B | $-1.40B | $-5.39B | $-6.48B | $-2.70B | $8.45B | $11.76B | $13.26B | $4.36B | $9.23B | $7.80B | $10.21B |
| Accounts receivable | $5.50B | $5.56B | $6.26B | $6.25B | $5.59B | $5.32B | $5.06B | $5.15B | $4.49B | $3.88B | $5.92B | $5.95B | $6.32B | $9.47B | $9.93B | $10.88B | $6.22B | $9.44B | $6.00B | $7.47B |
| Inventory | $2.44B | $3.06B | $4.06B | $4.06B | $3.84B | $3.87B | $3.97B | $3.90B | $4.23B | $4.72B | $5.10B | $5.56B | $5.48B | $7.88B | $8.20B | $7.83B | $5.15B | $7.01B | $5.67B | $5.92B |
| Goodwill | $758.00M | $1.37B | $2.10B | $3.36B | $3.61B | $3.75B | $4.36B | $4.21B | $3.72B | $5.16B | $5.96B | $5.73B | $5.79B | $13.99B | $14.49B | $14.29B | $7.05B | $8.68B | $6.98B | $7.02B |
Frequently asked questions
What is GlaxoSmithKline PLC ADR's revenue?
GlaxoSmithKline PLC ADR's trailing twelve-month revenue is $33.20B, and consensus projects about $60.50B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is GSK?
In its most recent fiscal year, GSK ran a gross margin of 72.40%, an operating margin of 24.28%, and a net margin of 17.50%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does GSK generate?
GSK produced $6.39B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is GSK's balance sheet healthy?
GSK holds $3.40B in cash and equivalents against $14.02B in long-term debt, on $16.38B of shareholder equity. That debt is best read against the cash flow the business throws off each year.